


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1 (currently amended). ~~Compounds~~ A compound where a ring structure (VIII)






representing a porphyrin, chlorin or bacteriochlorin/isobacteriochlorin ring in any of its iminonitrogen tautomeric forms carries four aromatic preferably phenyl substituents Ar each themselves carrying one or more hydroxy groups, one or more of which hydroxy groups is in turn linked to an antibody directed against a cell surface antigen of cancer or other diseased cells.

2 (currently amended). ~~Compounds~~ The compound according to claim 1 where the aromatic groups are m-hydroxy phenyl groups.

3 (currently amended). ~~Compounds~~ The compound according to claim 1 or claim 2 where the antibody is linked to the aromatic hydroxy group through a linking group, suitably an ether linked group particularly:-



where n is 1 to 4 and A is -OH or NH₂, or alternatively an ester-linked group particularly:-



where n and A are as before and R¹ is hydrogen or a hydrocarbon or carboxylated amino-acid side chain representing particularly glycine, alanine, lysine or glutamic acid.

4 (cancelled).

5 (currently amended). ~~Compounds~~ The compound according to claim 1, 2 or 3 wherein the antibody is an MAb, particularly mMAb-425 or an antibody to an antigen as listed herein.

6 (currently amended). ~~Compounds~~ The compound according to claim 1, 2 or 3, where VIII represents a porphyrin particularly m-THPP.

7 (currently amended). ~~Compounds~~ The compound according to claim 1, 2 or 3 where VIII represents a chlorin.

8 (currently amended). ~~Compounds~~ The compound according to claim 7 where VIII represents m-THPC.

9 (currently amended). ~~Compounds~~ The compound according to claim 7, where VIII represents a chlorin other than m-THPC, particularly p-THPC or o-THPC.

10 (currently amended). ~~Compounds~~ The compound according to claim 1, 2 or 3, where VIII represents a bacteriochlorin or isobacteriochlorin, particularly m-THPB or m-THPiB.

11 (currently amended). ~~The~~ Method of treatment of disease using an antibody conjugate according to ~~any one of claims 1 to 3 or 5 to 10 or prepared from an~~

~~intermediate according to claim 4~~claim 1 comprising administering said antibody
conjugate to a patient in need of such treatment.

12 (cancelled).

13 (new) The compound according to claim 1 where the aromatic
substituents are phenyl substituents.


14 (new). The compound according to claim 5 wherein the antibody is mMAb
425.

15 (new). The compound according to claim 6, where VIII represents m-
THPP.


16 (new). The compound according to claim 7, where VIII represents p-
THPC or o-THPC.

17 (new). The compound according to claim 10, where VIII represents m-
THPB or m-THPiB.




18(new). A compound where a ring structure (VIII)



representing a porphyrin, chlorine or bacteriochlorin/isobacteriochlorin ring in any of its iminonitrogen tautomeric forms carries four aromatic substituents Ar each themselves carrying one or more hydroxyl groups, one or more of which hydroxy groups is in turn linked to an antibody directed against a cell surface antigen of cancer or other diseased cells wherein the antibody is linked to the aromatic hydroxy group through an ether linked group:-



where n is 1 to 4 and A is -OH or NH₂, or alternatively an ester-linked group:-



where n and A are as before and R¹ is hydrogen or a hydrocarbon or carboxylated amino-acid side chain representing glycine, alanine, lysine or glutamic acid.